• Brand Name - Prolia
  • Innovator Brand Name - Prolia
  • API - Denosumab
  • Packaging - Single-use prefilled syringe
  • Strength - 60 mg
  • Manufacturer Name - Amgen


Denosumab is a RANKL inhibitor indicated:

  • for treating increased bone mass in males at the higher risk for the fracture receiving androgen deprivation therapy for the nonmetastatic prostate cancer. In such patients this drug also reduced the incidence of the vertebral fractures. 
  • for treating increased bone mass in females at the high risk for the fracture receiving adjuvant aromatase inhibitor therapy for the breast cancer. 
  • for treating the postmenopausal females with the osteoporosis at the higher risk for a fracture, defined as the history of the osteoporotic fracture, or multiple risk factors for the fracture; or patients who have failed or are intolerant to the other existing osteoporosis therapy. In postmenopausal female with the osteoporosis, Prolia helps in reducing the incidence of the vertebral, nonvertebral, and also hip fractures.
Denosumab Dosage

Denosumab injection should be administered by a healthcare professional. It should be Administered 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen.

Denosumab side effects
  • Postmenopausal osteoporosis: Most common adverse reactions include back pain, pain in extremity, hypercholesterolemia, cystitis, and musculoskeletal pain. Pancreatitis has been experienced in clinical trials.
  • Bone loss due to hormone ablation for cancer: Most common denosumab side effects include arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been experienced.
Warnings and Precautions
  • Patients must be instructed in order to take calcium 1000 mg daily and at least 400 IU vitamin D daily
  • If a prolia injection dosage is missed, administer the injection as soon as the patient is available. Thereafter, the injection should be scheduled every 6 months from the date of the last injection.
  • Patients should be advised that the denosumab is also marketed as Xgeva, and if patients are receiving Prolia, they should avoid receiving Xgeva.
  • Patients should be instructed in order to seek immediate medical assistance if they experience signs or symptoms of infections, including cellulitis.
  • Patients should be advised in order to seek immediate medical attention if they experience signs or symptoms of dermatological reactions such as rashes, eczema and dermatitis.
  • Prolia is not recommended in pediatric patients. The safety as well as the effectiveness profile of Denosumab in pediatric patients is unspecified.
  • Take a lot of care of your teeth as well as gums while taking this medication.
  • Patients must inform their healthcare provider or dentist if they observe persistent pain or slow healing of the mouth or jaw after the dental surgery.
  • No dose adjustment is required in patients with renal impairment.
  • Patients must be advised to seek immediate medical help if signs or symptoms of hypersensitivity reactions occur.
  • Patients should be instructed if they have had signs or symptoms of the systemic hypersensitivity reactions they must not receive denosumab.
  • Pregnancy status needs to be verified of females of reproductive potential before initiating treatment with Prolia 60 mg.
Supplied/Storage and handling

Care should be exercised in the handling of this injection. prolia injection should not be opened or crushed. Store is permitted between 2°C to 8°C (36°F to 46°F). Should be stored in the original carton. Do not freeze it.

Commonly asked questions:

Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL. It prevents RANKL from activating its receptor, preventing the RANKL/RANK interaction that inhibits osteoclast formation, function, and survival.

It is basically is a biologic drug recommended to use in order to prevent the fragile bones, also called osteoporosis and bone fractures.

Denosumab is the active ingredient in the single-use prefilled syringe composed with other inactive ingredients sorbitol, acetate, polysorbate 20, Water, and sodium hydroxide.

This drug may cause fetal harm. It is not recommended during pregnancy.

Treatment with Denosumab has the most common adverse reactions reported in patients with postmenopausal osteoporosis: back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.

  • You can buy Denosumab injection from any authorized whole seller after getting prescription from a qualified doctor. It is always better to check the credential of the whole seller/supplier/exporter before buying the product.
  • The buyer should check the existing law in their home country before importing the product.

Patients can simply fill the order form or can send mail at Patient can also send WhatsApp message to +91 8130290915. We will reply ASAP with the details of Pricing and procedure.
Note:- The order will be confirmed only after the receipt of Valid prescription of Clinician


All Trademark and Brand that appear on the website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. Denosumab is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller and Pharmacies.